Key Highlights
- Subsidiary Hubei Taihe Biotechnology will acquire the formulation, production process and registration rights for the product.
- The product already holds a China health food registration, which the company said avoids a lengthy new registration process.
- Planet Green plans to use licensed contract manufacturers instead of building its own production facilities.
- The global lactoferrin market is projected to grow from about US$278 million in 2026 to about US$519 million by 2034.
Planet Green Holdings Corp. (NYSEAM:PLAG), a diversified Holding Company headquartered in Flushing, New York, said its Subsidiary Hubei Taihe Biotechnology Co. has entered into a technology transfer agreement with Harbin Aikesailun Biotechnology Co. The agreement covers a registered immune-support health food product in the form of a chewable tablet combining bovine colostrum, vitamin C and lactoferrin.
Chairman and chief executive Bin Zhou described the agreement as a natural extension of the company’s lactoferrin strategy, saying it adds a ready-made formulation to an existing immunity product pipeline.
The agreement is structured as a technology transfer rather than a purchase of a company, which means Planet Green acquires specific rights, documentation and know-how tied to a single product.
Terms of the Technology Transfer
Under the agreement, Taihe Bio will acquire the product’s proprietary formulation, production process, quality standards and related technical know-how. It will also acquire the associated health food registration certificate rights in China. Aikesailun Bio will hand over technical documentation and provide process transfer support during the transition.
The two parties will jointly apply to China’s State Administration for Market Regulation to transfer the registration certificate to Taihe Bio. The transfer remains subject to regulatory approval, and the release did not disclose the purchase price for the rights.
The release sets out three elements of the transaction: the transfer of technical materials, the transfer of registration rights and the start of production through licensed contract Manufacturing partners.
The release describes the arrangement as a way to avoid the lengthy time and cost of registering a new health food product. By acquiring a product that already holds a registration, the company said it can move past much of that process.
Development Status and Market Context
The company said laboratory-scale and pilot-scale development of the product are complete, which positions it for the next phase of commercialization. Lactoferrin is a naturally occurring milk protein concentrated in colostrum and used in infant formula, supplements and sports nutrition products.
According to Market Data Forecast, the global lactoferrin market is expected to grow at a compound annual rate of approximately 8.1% through 2034. Grand View Research reported that China held the largest country share of the global market in 2025.
Planet Green describes its Business as diversified, ranging from consumer products to online advertising. The company operates through subsidiaries in China and Canada, and the acquired product would sit within its consumer products activities.
Production Model and Strategic Fit
Taihe Bio intends to engage qualified contract manufacturers that hold the required production licenses rather than build its own facilities. The company said this asset-light approach is designed to limit Capital spending and shorten the time to market.
The Acquisition extends the company’s previously announced lactoferrin sourcing, Marketing and distribution initiative, as well as its chewable immunity tablet program. The release did not state Revenue expectations or sales targets for the product.
The company said it intends to bring the product to commercial production through qualified contract manufacturers that hold the required production licenses. The release did not name those manufacturers or describe their capacity.
The release describes the product as a combination of three immune-support ingredients, which the company presents as the basis for its chewable tablet line. Lactoferrin is used in premium infant formula, supplements and sports nutrition products, according to the company.
Final Word
Planet Green’s agreement transfers a registered health food formulation, production know-how and registration rights to its Chinese subsidiary, using contract manufacturers rather than new facilities. The transfer requires regulatory approval before the product can move into commercial production.
The company’s announcement sets out the strategy and steps but does not provide financial terms, sales expectations or a timeline for launch. Subsequent filings and announcements will show how the product fits into the company’s immunity product line and its broader lactoferrin initiative.






Please wait processing your request...